ABSTRACT
Description: Rebetron is a combination therapy in which target patients are administered a combination of Intron A (Schering Corporation’s brand name for recombinant interferon α-2b; see Intron A monograph) and Rebetol (Schering Corporation’s brand name for ribavirin). Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3 carboxamide; C8H12N4O5) is a nucleoside analogue with antiviral activity. The product is supplied as a combination package containing rebetol capsules and intron A injection provided in either single-use or multidose vials or in a multidose pen.
